<DOC>
	<DOCNO>NCT02304406</DOCNO>
	<brief_summary>Thet study aim estimate prevalence ALK rearrangement Middle East North Africa population use Ventana ALK-IHC method ALK protein detection retrospective NSCLC clinical sample , &amp; evaluate association ALK rearrangement clinical pathological parameter NSCLC patient MENA .</brief_summary>
	<brief_title>Retrospective Epidemiology Study Of ALK Rearrangement In Non-Small Cell Lung Cancer Patients In The Middle East &amp; North Africa</brief_title>
	<detailed_description>This retrospective , cross-sectional non-interventional epidemiology study investigate prevalence ALK rearrangement NSCLC patient Middle East &amp; North Africa . Approximately 700 retain tumor tissue specimen ( tissue block ) patient previously diagnose NSCLC select &amp; subjected ALK immune-staining use Ventana anti-ALK ( D5F3 ) Rabbit Monoclonal Primary Antibody combine OptiView Benchmark System 6-8 center 5-7 country MENA region . The tissue sample NSCLC case retrieve tissue bank molecular diagnostic unit &amp; pathology department study center . The histological diagnosis confirm pathologist . The retained sample test perform Ventana ALK-IHC ass absence presence ALK rearrangement detection ALK protein formalin-fixed , paraffin-embedded NSCLC store tissue sample use Ventana anti-ALK ( D5F3 ) Rabbit Monoclonal Primary Antibody ( Roche Diagnostics GmbH ) select study center . The result ALK test within study population use establish prevalence ALK rearrangement MENA NSCLC patient . The patient ' characteristic , demographic , clinical pathologic parameter obtain medical record &amp; analyze determine association presence EML4-ALK fusion gene MENA NSCLC patient . The assessment concordance result FISH &amp; IHC do 2-3 center . Results FISH test collect &amp; record , retain tissue sample previously test . If , Vysis FISH test perform , assess concordance result obtain use Vysis Break-apart FISH &amp; Ventana IHC test method ALK rearrangement detection .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>1 . Histological confirmation nonsquamous NSCLC , TNM stage . 2 . Available sufficient tissue sample ALK test 3.Tissue sample less 5 year old 4.Routinely process formalinfixed , paraffinembedded tissue sample ( see exclusion criterion pertain tissue sample ) . 5.Histological section mount glass slide must older 3 month 6.Age &gt; 18 year 7.Any ECOG Performance status 8.Still alive , death confirm inclusion , unknown 9.Disease diagnosis and/or treatment one center , last 5 year , assign participate study ; 10.Written inform consent general investigational test previously obtain , specifically obtain retrospective epidemiology study , document waiver Informed consent document use , required local regulatory authority , &amp; /or Research Ethics committee/Institutional Review Board . 1 Tumor tissue sample older 5 year period sample properly store . 2Tumor tissue sample fix use AFA , B5 , Bouin 's , 95 % ETOH , &amp; alcohol fixative . 3Underfixed tissue sample ( i.e . &lt; 6 hr ) 4Tumor tissue sample subject decalcification process . 5Recycled paraffinembedded tissue sample . 6Cut slide store longer 3 month . 7Insufficient tissue sample less tumor cell &amp; high amount necrosis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>prevalence ALK rearrangement , NSCLC , MENA</keyword>
</DOC>